Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.

Zhi PengTianshu LiuJia WeiAirong WangYifu HeLiuzhong YangXizhi ZhangNanfeng FanSuxia LuoZhen LiKangsheng GuJianwei LuJianming XuQingxia FanRuihua XuLiangming ZhangEnxiao LiYuping SunGuohua YuChunmei BaiYong LiuJiangzheng ZengJieer YingXinjun LiangNong XuChao GaoYongqian ShuDong MaGuanghai DaiShengmian LiTing DengYuehong CuiJianmin FangYi BaLin Shen

Published in: Cancer communications (London, England) (2021)

RC48 showed promising activity with manageable safety, suggesting potential application in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy.

Keyphrases

locally advanced
phase ii study
squamous cell carcinoma
papillary thyroid
rectal cancer
neoadjuvant chemotherapy
squamous cell
radiation therapy
open label
small cell lung cancer
lymph node metastasis
risk assessment
human health
study protocol